Open Targets Beyond associations: building therapeutic hypotheses with Open Targets [5 minute read] Open Targets directors Ian Dunham and David Hulcoop describe the elements of a full therapeutic hypothesis, and how Open Targets is working to enable the systematic assessment of such hypotheses.
Guest Speakers Open Targets hosts Kiran Musunuru: insights into the genetic basis of coronary heart disease [7 minute read] Open Targets recently hosted Prof. Kiran Musunuru, who discussed his work into the genetic basis of coronary heart disease.
Open Targets How Open Targets is investigating 100 chromatin-related disorders | Rare Disease Day 2021 [5 minute read] Sebastian Gerety is a Senior Staff Scientist at the Wellcome Sanger Institute who oversees the the 100 chromatin-related disorders project. In honour of Rare Disease Day 2021, he told us about what they have been working on.
Open Targets Platform How we improved our clinical trial curation during the COVID-19 lockdown Learn how we leveraged the wide range of expertise amongst our lab-based experimental research colleagues to make valuable contributions to the Open Targets Platform and our target validation projects.
Open Targets Platform The importance of Autophagy in drug discovery Explore Reactome's new autophagy pathway and how it relates to drug discovery and the Open Targets Platform
coronavirus infectious disease Open Targets releases our COVID-19 Target Prioritisation Tool Open Targets is excited to introduce our COVID-19 Target Prioritisation Tool - http://covid19.opentargets.org/ - an interactive web portal allows users to explore host and viral targets and potential COVID-19 treatments
release notes Open Targets Platform 20.04 has been released! We have a new release of the Open Targets Platform with new target safety data, new target tractability modalities, more chemical probes and new associations.
Open Targets Genetics GWAS causal inference in Open Targets Finding GWAS causal inference for target identification and prioritisation using Open Targets Genetics and the Open Targets Platform.
Q&A Special Q&A with Gosia Trynka, Open Targets Experimental Science director We're delighted to have caught up with Gosia Trynka, our new Experimental Science director, for a very special Q&A on Open Targets science and more.
release notes Open Targets Platform 20.02 has been released! We have a new release of the Open Targets Platform with a brand new data source, Open Targets Genetics Portal, more chemical probes and new intOGen data.
Cancer An Open Targets Away Day with The Institute of Cancer Research Open Targets meets colleagues at the Institute of Cancer Research in London: potential collaboration ahead of us.
ontology EFO3: A community-driven ontology to advance clinical discoveries In the 19.11 release of the Open Targets Platform, we moved from EFO2 to EFO3. Here we explore what the new disease ontology means to Open Targets.
Open Targets Platform Using ChEMBL for target identification and prioritisation Open Targets Q&A on the identification of cancer driver genes and their mechanism of action using intOGen. Using ChEMBL for target identification and prioritisation
release notes Open Targets Platform: release 19.11 is out We have a new release of the Open Targets Platform: new EFO3, FDA pharmacovigilance data, new chemical probes, more targets, more evidence and associations.
A-Z From antibody to zinc finger, an A-Z of Open Targets: H As scientists discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. November is time for H.
release notes Open Targets Platform: release 19.09 is out We have a new release of the Open Targets Platform: more target-disease associations, more chemical probes and target enabling packages, and updated Elasticsearch.
A-Z From antibody to zinc finger, an A-Z of Open Targets: F and G As users discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. This time we have a double bill: F and G.
release notes Open Targets Platform: release 19.06 is out We have a new release of the Open Targets Platform: more target safety information and new target-disease associations are some of the highlights in release 19.06.
Q&A Using CRISPR priority score to identify targets in cancer drug discovery Open Targets Q&A on the first set of CRISPR screen results in cancer for target identification and prioritisation in drug discovery.
release notes Open Targets Platform: release 19.04 is out We have a new release of the Open Targets Platform: CRISPR-Cas9 data and target safety information are some of the highlights in release 19.04.
A-Z From antibody to zinc finger, an A-Z of Open Targets: E As users discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. March is time for E.
release notes Open Targets Platform: release 19.02 is out Our latest release of the Open Targets Platform is out. We have more targets, more diseases, more evidence, more associations, and fixed some bugs too.
A-Z From antibody to zinc finger, an A-Z of Open Targets: D As users discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. It's D-time.
release notes Open Targets Platform: release 18.08 is out The latest release of the Open Targets Platform is out. We have more evidence, new targets, new diseases and new associations, plus data from Probe Miner.
Open Targets Platform Get to know the Reactome enhanced pathway visualisations Open Targets Q&A on the new Reactome pathway visualisations: scalable, interactive textbook-style diagrams in SVG format, freely downloadable and editable.
